Open-label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures

Steven C. Schachter, William T Cahill, Braxton B. Wannamaker, Vincent S. Shu, Kenneth W. Sommerville

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This study was designed to determine the highest tiagabine dosage that could be administered as monotherapy to patients with complex partial seizures refractory to treatment with other antiepileptic drugs (AEDs) without unacceptable adverse events. Thirty-one patients, 18-47 years of age, participated at three sites. During a 3-week initiation phase, tiagabine was started and the dosage increased while concomitant AED dosage was reduced. During a 7-week dose-evaluation phase, dosage was adjusted until the maximum tolerated dosage was reached. During the dose termination phase, patients tolerating the drug entered a long-term open-label study of tiagabine monotherapy. Of 31 patients, 19 converted to monotherapy; in 12 cases, monotherapy was tolerated well enough to be continued for 7 weeks. Of the 12 nonconverters, seven left during the initiation phase due to adverse events and five due to inadequate seizure control. Most events were mildly or moderately severe and were associated with the central nervous system. Plasma tiagabine concentrations were similar in both converters and nonconverters. Conversion to tiagabine monotherapy was accomplished in most patients with difficult-to-control seizures when previous AED monotherapy was replaced in under 4 weeks. The ideal dosage appeared to be approximately 38 mg/day given in three divided doses.

Original languageEnglish (US)
Pages (from-to)248-255
Number of pages8
JournalJournal of Epilepsy
Volume11
Issue number5
DOIs
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Seizures
Anticonvulsants
Central Nervous System
tiagabine
Pharmaceutical Preparations
Therapeutics

Keywords

  • Administration and dosage
  • Complex partial epilepsy
  • Drug tolerance
  • GABA antagonists
  • Tiagabine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Open-label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures. / Schachter, Steven C.; Cahill, William T; Wannamaker, Braxton B.; Shu, Vincent S.; Sommerville, Kenneth W.

In: Journal of Epilepsy, Vol. 11, No. 5, 09.1998, p. 248-255.

Research output: Contribution to journalArticle

Schachter, Steven C. ; Cahill, William T ; Wannamaker, Braxton B. ; Shu, Vincent S. ; Sommerville, Kenneth W. / Open-label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures. In: Journal of Epilepsy. 1998 ; Vol. 11, No. 5. pp. 248-255.
@article{0c73185ac4e84fa7ad3ac9c347a34563,
title = "Open-label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures",
abstract = "This study was designed to determine the highest tiagabine dosage that could be administered as monotherapy to patients with complex partial seizures refractory to treatment with other antiepileptic drugs (AEDs) without unacceptable adverse events. Thirty-one patients, 18-47 years of age, participated at three sites. During a 3-week initiation phase, tiagabine was started and the dosage increased while concomitant AED dosage was reduced. During a 7-week dose-evaluation phase, dosage was adjusted until the maximum tolerated dosage was reached. During the dose termination phase, patients tolerating the drug entered a long-term open-label study of tiagabine monotherapy. Of 31 patients, 19 converted to monotherapy; in 12 cases, monotherapy was tolerated well enough to be continued for 7 weeks. Of the 12 nonconverters, seven left during the initiation phase due to adverse events and five due to inadequate seizure control. Most events were mildly or moderately severe and were associated with the central nervous system. Plasma tiagabine concentrations were similar in both converters and nonconverters. Conversion to tiagabine monotherapy was accomplished in most patients with difficult-to-control seizures when previous AED monotherapy was replaced in under 4 weeks. The ideal dosage appeared to be approximately 38 mg/day given in three divided doses.",
keywords = "Administration and dosage, Complex partial epilepsy, Drug tolerance, GABA antagonists, Tiagabine",
author = "Schachter, {Steven C.} and Cahill, {William T} and Wannamaker, {Braxton B.} and Shu, {Vincent S.} and Sommerville, {Kenneth W.}",
year = "1998",
month = "9",
doi = "10.1016/S0896-6974(98)00024-3",
language = "English (US)",
volume = "11",
pages = "248--255",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Open-label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures

AU - Schachter, Steven C.

AU - Cahill, William T

AU - Wannamaker, Braxton B.

AU - Shu, Vincent S.

AU - Sommerville, Kenneth W.

PY - 1998/9

Y1 - 1998/9

N2 - This study was designed to determine the highest tiagabine dosage that could be administered as monotherapy to patients with complex partial seizures refractory to treatment with other antiepileptic drugs (AEDs) without unacceptable adverse events. Thirty-one patients, 18-47 years of age, participated at three sites. During a 3-week initiation phase, tiagabine was started and the dosage increased while concomitant AED dosage was reduced. During a 7-week dose-evaluation phase, dosage was adjusted until the maximum tolerated dosage was reached. During the dose termination phase, patients tolerating the drug entered a long-term open-label study of tiagabine monotherapy. Of 31 patients, 19 converted to monotherapy; in 12 cases, monotherapy was tolerated well enough to be continued for 7 weeks. Of the 12 nonconverters, seven left during the initiation phase due to adverse events and five due to inadequate seizure control. Most events were mildly or moderately severe and were associated with the central nervous system. Plasma tiagabine concentrations were similar in both converters and nonconverters. Conversion to tiagabine monotherapy was accomplished in most patients with difficult-to-control seizures when previous AED monotherapy was replaced in under 4 weeks. The ideal dosage appeared to be approximately 38 mg/day given in three divided doses.

AB - This study was designed to determine the highest tiagabine dosage that could be administered as monotherapy to patients with complex partial seizures refractory to treatment with other antiepileptic drugs (AEDs) without unacceptable adverse events. Thirty-one patients, 18-47 years of age, participated at three sites. During a 3-week initiation phase, tiagabine was started and the dosage increased while concomitant AED dosage was reduced. During a 7-week dose-evaluation phase, dosage was adjusted until the maximum tolerated dosage was reached. During the dose termination phase, patients tolerating the drug entered a long-term open-label study of tiagabine monotherapy. Of 31 patients, 19 converted to monotherapy; in 12 cases, monotherapy was tolerated well enough to be continued for 7 weeks. Of the 12 nonconverters, seven left during the initiation phase due to adverse events and five due to inadequate seizure control. Most events were mildly or moderately severe and were associated with the central nervous system. Plasma tiagabine concentrations were similar in both converters and nonconverters. Conversion to tiagabine monotherapy was accomplished in most patients with difficult-to-control seizures when previous AED monotherapy was replaced in under 4 weeks. The ideal dosage appeared to be approximately 38 mg/day given in three divided doses.

KW - Administration and dosage

KW - Complex partial epilepsy

KW - Drug tolerance

KW - GABA antagonists

KW - Tiagabine

UR - http://www.scopus.com/inward/record.url?scp=0032170041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032170041&partnerID=8YFLogxK

U2 - 10.1016/S0896-6974(98)00024-3

DO - 10.1016/S0896-6974(98)00024-3

M3 - Article

AN - SCOPUS:0032170041

VL - 11

SP - 248

EP - 255

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 5

ER -